Switzerland Approves Second Covid Vaccine For Young People

The Swissmedic regulatory authority, which has already approved the Pfizer-BioNTech jab for over-12s, said results from an ongoing study showed Moderna had 93 percent efficacy in the young age group.

Switzerland on Monday approved Moderna's Covid-19 vaccine for youngsters aged between 12 and 17 years old, weeks after EU regulators authorised the drug for the same age group. The Swissmedic regulatory authority, which has already approved the Pfizer-BioNTech jab for over-12s, said results from an ongoing study showed Moderna had 93 percent efficacy in the young age group. "The vaccine produced a similar immune response... in this study compared to young adults aged 18 to 25 years," the regulator said. Switzerland, which is not in the European Union, has its own regulatory process and was the first country in continental Europe to start using the Pfizer-BioNTech jab.